Skip to content
lifestyle.successxl.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Vascarta Inc
Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients
June 24, 2026
Vascarta Announces Addition of Richard Serbin to Leadership Team
June 9, 2026
Vascarta Announces Positive Clinical Trial Results for Topical/Transdermal Curcumin Gel VAS-101 in Knee Osteoarthritis
April 1, 2026
Novel Transdermal Curcumin (VAS-101) Improves Cardiac Mitochondrial Function in Sickle Cell Disease Mouse Model, New FDA Led Study Shows
December 4, 2025